By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
DiaMedica Therapeutics Inc. insiders have been one-way buyers this past year: one person put roughly $7.6 million into the stock and nobody sold with their own money.
Biggest single buyer: TRILL AB, 10% Owner, with roughly $1.7 million.
On the institutional side, 89 funds reported holding DMAC at the end of Q2 2026, and funds were split between buying and selling. Zooming out by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 2 of the last 7 full quarters.
Are insiders buying or selling DMAC stock?
In the last 12 months DiaMedica Therapeutics Inc. insiders made open-market purchases worth about $7.6 million and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in DMAC?
The most recent open-market insider trade in DMAC was filed on 2025-12-08.
How many institutions own DMAC?
89 investment managers reported holding DMAC in SEC Form 13F filings for Q2 2026.
Has any member of Congress traded DMAC?
No congressional trades in DMAC were reported in the past two years. The full list is free on CapitalSnitch.
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).